Price movement over the last 24 hours
Global X FTSE Southeast Asia ETF vs Johnson & Johnson — how do they compare? Global X FTSE Southeast Asia ETF trades at $20.65, while Johnson & Johnson trades at $257.48 (market cap $618.61B). The key difference: Johnson & Johnson pays a 2.09% dividend while Global X FTSE Southeast Asia ETF pays none. Which is the better fit depends on your goals.
| ASEA | JNJ | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $20.65 | $267.24 |
52-Week Low | $16.31 | $155.17 |
Market Cap | — | $618.61B |
Volume | — | 6,156,228 |
Enterprise Value | — | $651.54B |
Dividend Yield | — | 2.09% |
Signals from Pluang's Aura AI — not financial advice
ASEA stock trades at $20.65, up 0.63% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong momentum with an ADX of 49.11 indicating a trending market. Recent corporate actions include a declared dividend of $0.41 per share scheduled for July 2026. Key support and resistance levels are clustered around $20-$21, suggesting a critical price zone for near-term direction.
The outlook remains cautiously optimistic given technical strength, but fundamental data is currently unavailable for a complete assessment. Risks include potential volatility near key technical levels and reliance on future financial performance disclosures. Investors should await upcoming earnings reports for clarity on valuation and profitability metrics.
Johnson & Johnson (JNJ) trades at $256.98, down 0.82% today, with a bullish technical signal from moving averages and a consensus analyst price target of $268.50. The company reported strong Q1 2026 EPS of $2.70, beating expectations, and maintains robust profitability with a net income margin of 21.83%. Recent news highlights dividend growth strategies and comparisons with peers like AbbVie, while cash flow trends show operational strength despite negative net cash flow in 2025.
JNJ presents a stable investment opportunity with consistent earnings beats and a solid dividend, but faces risks from rising debt levels and competitive pressures. The stock's current valuation metrics, including a P/E of 29.78, suggest it is fairly valued with moderate upside potential based on analyst targets. Investors should weigh the company's strong fundamentals against macroeconomic and sector-specific headwinds.
Trailing returns across standard periods
Latest headlines on both assets
ASEA tracks the performance of the largest companies in Southeast Asia. It provides exposure to key emerging markets including Singapore, Indonesia, Thailand, and Malaysia, with a heavy focus on financials like DBS Group and Bank Central Asia.
Read more on ASEA →Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →